184 related articles for article (PubMed ID: 10699927)
61. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
62. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
[TBL] [Abstract][Full Text] [Related]
63. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
Chen M; Beck WT
Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
[TBL] [Abstract][Full Text] [Related]
64. A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents.
Hashimoto S; Danks MK; Chatterjee S; Beck WT; Berger NA
Oncol Res; 1995; 7(1):21-9. PubMed ID: 7549041
[TBL] [Abstract][Full Text] [Related]
65. A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429.
Campain JA; Gottesman MM; Pastan I
Biochemistry; 1994 Sep; 33(37):11327-32. PubMed ID: 7727383
[TBL] [Abstract][Full Text] [Related]
66. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
67. Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line.
Binaschi M; Giaccone G; Gazdar AF; De Isabella P; Ricotti GC; Capranico G; Zunino F
J Natl Cancer Inst; 1992 Nov; 84(22):1710-6. PubMed ID: 1331483
[TBL] [Abstract][Full Text] [Related]
68. HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha.
Stros M; Polanská E; Struncová S; Pospísilová S
Nucleic Acids Res; 2009 Apr; 37(7):2070-86. PubMed ID: 19223331
[TBL] [Abstract][Full Text] [Related]
69. Modulation of topoisomerase IIα expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide.
Pett L; Kiakos K; Satam V; Patil P; Laughlin-Toth S; Gregory M; Bowerman M; Olson K; Savagian M; Lee M; Lee M; Wilson WD; Hochhauser D; Hartley JA
Biochim Biophys Acta Gene Regul Mech; 2017 May; 1860(5):617-629. PubMed ID: 27750031
[TBL] [Abstract][Full Text] [Related]
70. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
71. Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity.
Uesaka T; Shono T; Kuga D; Suzuki SO; Niiro H; Miyamoto K; Matsumoto K; Mizoguchi M; Ohta M; Iwaki T; Sasaki T
J Neurooncol; 2007 Sep; 84(2):119-29. PubMed ID: 17361331
[TBL] [Abstract][Full Text] [Related]
72. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
[TBL] [Abstract][Full Text] [Related]
73. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
74. Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells.
Hong Y; Sang M; Shang C; Xue YX; Liu YH
Neurosci Lett; 2012 Jun; 518(2):138-43. PubMed ID: 22569122
[TBL] [Abstract][Full Text] [Related]
75. DNA topoisomerase IIalpha protein and mRNA expression in intracranial meningiomas.
Kunishio K; Morisaki K; Matsumoto Y; Nagao S
Brain Tumor Pathol; 2000; 17(3):105-10. PubMed ID: 11310917
[TBL] [Abstract][Full Text] [Related]
76. Nuclear factor-Y binding to the topoisomerase IIalpha promoter is inhibited by both the p53 tumor suppressor and anticancer drugs.
Joshi AA; Wu Z; Reed RF; Suttle DP
Mol Pharmacol; 2003 Feb; 63(2):359-67. PubMed ID: 12527807
[TBL] [Abstract][Full Text] [Related]
77. Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.
Asano T; Nakamura K; Fujii H; Horichi N; Ohmori T; Hasegawa K; Isoe T; Adachi M; Otake N; Fukunaga Y
Br J Cancer; 2005 Apr; 92(8):1486-92. PubMed ID: 15798770
[TBL] [Abstract][Full Text] [Related]
78. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Prost S; Riou G
Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
[TBL] [Abstract][Full Text] [Related]
79. ATF is important to late S phase-dependent regulation of DNA topoisomerase IIalpha gene expression in HeLa cells.
Son MY; Kim TJ; Kweon KI; Park JI; Park C; Lee YC; No Z; Ahn JW; Yoon WH; Park SK; Lim K; Hwang BD
Cancer Lett; 2002 Oct; 184(1):81-8. PubMed ID: 12104051
[TBL] [Abstract][Full Text] [Related]
80. Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II alpha.
Kuriyama M; Tsutsui K; Tsutsui K; Ono Y; Tamiya T; Matsumoto K; Furuta T; Ohmoto T
Neurol Med Chir (Tokyo); 1997 Sep; 37(9):655-61; discussion 661-2. PubMed ID: 9330528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
